Skip Ribbon Commands
Skip to main content

QuiremScout®

Microspheres

Description

SELECT THE RIGHT PATIENTS, WITH CONFIDENCE

QuiremScout®: the first SIRT work-up product that uses the same technology as the therapeutic
microspheres, to optimize patient selection and advance treatment planning

Characteristics

QuiremScout®:
  • Contains the same microspheres as QuiremSpheres®(1)
  • has been shown to be safe in a study of 82 patients (2,3)
  • has been shown to be a better predictor for lung shunt and intrahepatic distribution than 99mTc-MAA (4,5)
  • has been shown to be more accurate at treatment planning than 99mTc-MAA, ensuring the right patients are identified for SIRT (6–8)

Preparation

Video instructions

 

Clinical evidence

See all clinical evidence

General specifications

​Characteristics
​99mTc-MAA
​QuiremScout®
​QuiremSpheres®
Particle Morphology​MAA.JPG
microsphere.JPG
microsphere.JPG
​Material
​MAA
​PLLA
​PLLA
​Particle size (µm)
​1 - 150
​30 (15-60)
​30 (15-60)
​Number of particles (million)
​0.2 - 1.2
​3
​30
​Gamma energy
​141 keV
​81 keV
​81 keV

QuiremScout® is a product manufactured by Quirem Medical B.V and has CE-mark.

QuiremScout® is not available for sales in all countries. This information is provided only in respect to markets where the product is approved and cleared. 

QuiremScout® is not FDA cleared in the US. 

Item specifications

​Item reference
​Material description
​Description
​QS-S001

​QuiremScout®

​V-vial containing a small quantity of low-dose holmium-166 microspheres
​QS-C001
​Customer kit

​Set of re-usable administration box and accessories for administration of QuiremSpheres®

​QS-D001
​Delivery set

​Set of sterile single-use tube lines for administration of QuiremSpheres® (in a carton of 6 pieces)


References

1 QuiremScout® 166Ho-Scout – Instruction for use
2 Braat et al. Eur Radiol 2018;28:920–28
3 Prince et al. J Nucl Med 2015;56:817–23
4. Elschot et al. Eur J Nucl Med Mol Imaging 2014;41:1965–75
5. Dassen et al. Presented at CIRSE 2018. Abstract available at: https://library.cirse.org/cirse2018/crs/the-predictive-value-of-theintrahepatic-
distribution-of-99mtc-macroaggregated-albumin-and-holmium-166-scout-dose-prior-to-holmium-166-radioembolization
6. Grosche-Schlee et al. QuiremScout® case study. Available at: https://www.terumo-europe.com/en-emea/clinical-program/Clinical%20
Data/E_Clinical_Case_Studies_QuiremScout_LR.PDF#search=SIRT%20case%20study
7. Smits et al. Eur J Nucl Med Mol Imaging 2020;47:798–806
8. Chiesa and Maccauro. Eur J Nucl Med Mol Imaging 2020;47:744–47

Do you need more info?

Our sales representatives are here for you

Contact us

Didn't find your product?

Consult our products in our Product Index

Are you a healthcare professional?

This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public